Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
-0.38% $0.680
America/New_York / 25 apr 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 0.458 mill |
EPS: | -67.07 |
P/E: | -0.0100 |
Earnings Date: | May 08, 2024 |
SharesOutstanding: | 0.673 mill |
Avg Daily Volume: | 0.276 mill |
RATING 2024-04-25 |
---|
B- |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Buy | |
Return On Equity: | Strong Sell | |
Return On Asset: | Strong Sell | |
DE: | Buy | |
P/E: | Neutral | |
Price To Book: | Sell |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | n/a | n/a | n/a | n/a | n/a | |
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -0.0100 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
0.00x |
Company: PE -0.0100 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
N/A |
N/A |
Expected Trading Range (DAY) |
---|
$ -0.0700 - 1.430 ( +/- 110.29%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-04 | Taylor Daphne | Buy | 1 584 | Common Stock |
2024-03-02 | Taylor Daphne | Buy | 3 667 | Common Stock |
2024-03-02 | Taylor Daphne | Sell | 3 667 | Restricted Stock Unit |
2024-03-04 | Taylor Daphne | Sell | 1 584 | Restricted Stock Unit |
2024-03-03 | Lamothe Jeffrey G. | Buy | 3 667 | Common Stock |
INSIDER POWER |
---|
28.00 |
Last 99 transactions |
Buy: 423 660 | Sell: 158 934 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $0.680 (-0.38% ) |
Volume | 0.341 mill |
Avg. Vol. | 0.276 mill |
% of Avg. Vol | 123.63 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Its lead clinical candidate is APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelodysplastic syndrome. The company's preclinical candidates also include ALG.APV-527, an investigational bispecific ADAPTIR candidate that features a mechanism of action to target 4-1BB (CD137) and 5T4, a tumor antigen expressed in various types of cancers; and APVO603, a dual agonist bispecific antibody to target 4-1BB and OX40. It also develoes APVO442, a bispecific candidate based on the ADAPTIR-FLEX platform technology to enhance biodistribution of drugs to PSMA positive tumors for treatment of prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.